Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Crohn’s disease
IL-23
therapeutic drug monitoring
trough concentrations
ustekinumab
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
05 07 2023
05 07 2023
Historique:
received:
04
02
2022
medline:
6
7
2023
pubmed:
3
8
2022
entrez:
2
8
2022
Statut:
ppublish
Résumé
Ustekinumab (UST), which targets p40/interleukin (IL)-23 and IL-12, is an effective treatment for Crohn's disease (CD). Therapeutic drug monitoring may optimize UST posology. The aim of this study was to investigate UST and IL-23 serum and tissue concentrations in relation to mucosal inflammation and treatment response at an early time point. CD patients starting UST between December 2016 and November 2018 were prospectively enrolled. Endoscopies were performed at baseline and week 16. UST and IL-23 serum and tissue concentrations were measured at week 16. Clinical and biochemical response were defined as decline of ≥3 points in Harvey-Bradshaw Index and reduction of ≥50% in fecal calprotectin levels. Endoscopic response was defined as a ≥50% decline in Simple Endoscopic Score or a decline of ≥1 points in Rutgeerts score. Histological remission was defined as Global Histologic Disease Activity Score ≤4. Of 56 included patients, 17 (30%) of 56 showed clinical response, 16 (30%) of 53 showed biochemical response, and 20 (36%) of 56 showed endoscopic response. UST, but not IL-23, concentration in biopsies was correlated to levels in corresponding sera (P < .0001). No correlation was found between UST tissue levels and treatment response. Patients achieving biochemical response showed significantly higher UST serum levels (3.12 µg/mL vs 1.41 µg/mL; P = .01). Tissue IL-23-to-UST ratio correlated with mucosal inflammation (P = .01). This is the first study to demonstrate a correlation between serum and tissue UST levels. While tissue IL-23-to-UST ratio correlated with mucosal inflammation, UST serum levels were more indicative for biochemical response. The role of UST levels for therapeutic drug monitoring in inflammatory bowel disease needs further research. Ustekinumab (UST) serum levels correlate with UST tissue levels in patients with Crohn’s disease. Tissue interleukin-23-to-UST ratio correlates with histological inflammation (Global Histologic Disease Activity Score). Serum UST levels correlate with biochemical response (reduction of ≥50% in fecal calprotectin levels).
Sections du résumé
BACKGROUND
Ustekinumab (UST), which targets p40/interleukin (IL)-23 and IL-12, is an effective treatment for Crohn's disease (CD). Therapeutic drug monitoring may optimize UST posology. The aim of this study was to investigate UST and IL-23 serum and tissue concentrations in relation to mucosal inflammation and treatment response at an early time point.
METHODS
CD patients starting UST between December 2016 and November 2018 were prospectively enrolled. Endoscopies were performed at baseline and week 16. UST and IL-23 serum and tissue concentrations were measured at week 16. Clinical and biochemical response were defined as decline of ≥3 points in Harvey-Bradshaw Index and reduction of ≥50% in fecal calprotectin levels. Endoscopic response was defined as a ≥50% decline in Simple Endoscopic Score or a decline of ≥1 points in Rutgeerts score. Histological remission was defined as Global Histologic Disease Activity Score ≤4.
RESULTS
Of 56 included patients, 17 (30%) of 56 showed clinical response, 16 (30%) of 53 showed biochemical response, and 20 (36%) of 56 showed endoscopic response. UST, but not IL-23, concentration in biopsies was correlated to levels in corresponding sera (P < .0001). No correlation was found between UST tissue levels and treatment response. Patients achieving biochemical response showed significantly higher UST serum levels (3.12 µg/mL vs 1.41 µg/mL; P = .01). Tissue IL-23-to-UST ratio correlated with mucosal inflammation (P = .01).
CONCLUSIONS
This is the first study to demonstrate a correlation between serum and tissue UST levels. While tissue IL-23-to-UST ratio correlated with mucosal inflammation, UST serum levels were more indicative for biochemical response. The role of UST levels for therapeutic drug monitoring in inflammatory bowel disease needs further research.
Ustekinumab (UST) serum levels correlate with UST tissue levels in patients with Crohn’s disease. Tissue interleukin-23-to-UST ratio correlates with histological inflammation (Global Histologic Disease Activity Score). Serum UST levels correlate with biochemical response (reduction of ≥50% in fecal calprotectin levels).
Autres résumés
Type: plain-language-summary
(eng)
Ustekinumab (UST) serum levels correlate with UST tissue levels in patients with Crohn’s disease. Tissue interleukin-23-to-UST ratio correlates with histological inflammation (Global Histologic Disease Activity Score). Serum UST levels correlate with biochemical response (reduction of ≥50% in fecal calprotectin levels).
Identifiants
pubmed: 35917118
pii: 6653348
doi: 10.1093/ibd/izac169
pmc: PMC10320373
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
Interleukin-12
187348-17-0
Interleukin-23
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1038-1046Informations de copyright
© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Immunity. 2019 Aug 20;51(2):367-380.e4
pubmed: 31350179
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
Dig Dis Sci. 2020 May;65(5):1445-1452
pubmed: 31599389
Clin Gastroenterol Hepatol. 2010 Apr;8(4):357-63
pubmed: 20096379
Med Sci Monit. 2020 Jan 07;26:e920371
pubmed: 31910201
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2610-2612
pubmed: 30851477
Cytokine Growth Factor Rev. 2019 Feb;45:1-8
pubmed: 30563755
United European Gastroenterol J. 2020 May;8(4):418-424
pubmed: 32213026
JAMA. 2021 Jan 05;325(1):69-80
pubmed: 33399844
J Gastroenterol Hepatol. 2020 Jul;35(7):1163-1170
pubmed: 31860733
Gut. 2016 Feb;65(2):249-55
pubmed: 25670812
Expert Opin Biol Ther. 2020 Feb;20(2):193-203
pubmed: 31859538
Clin Gastroenterol Hepatol. 2021 Jan;19(1):111-118.e10
pubmed: 32109630
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):185-196
pubmed: 30478416
Gastroenterology. 2018 May;154(6):1660-1671
pubmed: 29409871
Arthritis Rheumatol. 2019 Oct;71(10):1660-1669
pubmed: 31070869
Cochrane Database Syst Rev. 2017 Jul 21;7:CD012351
pubmed: 28731502
Medicine (Baltimore). 2016 Jun;95(23):e3772
pubmed: 27281077
World J Gastroenterol. 2019 Aug 21;25(31):4481-4492
pubmed: 31496626
J Crohns Colitis. 2019 Jul 25;13(7):864-872
pubmed: 30715258
Crohns Colitis 360. 2020 Jul 28;2(4):otaa061
pubmed: 36777754
J Dermatol. 2010 May;37(5):413-25
pubmed: 20536646
J Clin Pharmacol. 2020 Jul;60(7):889-902
pubmed: 32026499
Z Gastroenterol. 2020 May;58(5):439-444
pubmed: 32045954
Clin Gastroenterol Hepatol. 2017 Sep;15(9):1427-1434.e2
pubmed: 28365485
Immunity. 2018 Aug 21;49(2):342-352.e5
pubmed: 30097293
J Leukoc Biol. 2011 Apr;89(4):597-606
pubmed: 21227898